标题
TEMPORARY REMOVAL: SGLT inhibitors for improving healthspan and lifespan
作者
关键词
-
出版物
PROGRESS IN CARDIOVASCULAR DISEASES
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2023-10-17
DOI
10.1016/j.pcad.2023.10.003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
- (2023) Dae Jung Kim et al. Journal of Diabetes Investigation
- Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls
- (2023) Joshua Stevenson-Hoare et al. BMC PUBLIC HEALTH
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival
- (2023) Juhua Luo et al. BRITISH JOURNAL OF CANCER
- Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
- (2023) Huilin Tang et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
- (2023) Cheuk To Chung et al. Cancer Medicine
- Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
- (2023) Shih-Wei Lai et al. Frontiers in Endocrinology
- Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events
- (2023) Niels A. Stens et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats
- (2022) Moein Ala et al. Oxidative Medicine and Cellular Longevity
- Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
- (2022) Brendon L. Neuen et al. CIRCULATION
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
- (2022) Chen Cai et al. Redox Biology
- Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
- (2022) Milton Packer CIRCULATION
- Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study
- (2022) Matthew Thomas Keys et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
- (2022) Muthiah Vaduganathan et al. LANCET
- Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- (2022) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study
- (2022) Che-Yuan Wu et al. DIABETES CARE
- Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer
- (2022) Cho-Han Chiang et al. HEART
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
- (2022) Colin Baigent et al. LANCET
- Empagliflozin in Patients with Chronic Kidney Disease
- (2022) NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin alleviates ethanol‐induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway
- (2021) Ge Tian et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials
- (2021) Yao Hao Teo et al. Journal of the American Heart Association
- Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure
- (2021) Xuan Li et al. Journal of the American Heart Association
- The role of autophagy in cardiovascular pathology
- (2021) Damián Gatica et al. CARDIOVASCULAR RESEARCH
- The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis
- (2021) Peter Cox et al. RHEUMATOLOGY INTERNATIONAL
- The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
- (2021) Vincenzo Quagliariello et al. Cardiovascular Diabetology
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
- (2021) Arjun K. Pandey et al. Journal of the American Heart Association
- Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
- (2021) Dao-Gen Yin et al. Frontiers in Pharmacology
- Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress
- (2021) Fang-fang Ren et al. ACTA PHARMACOLOGICA SINICA
- SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney
- (2021) Qingqing Ke et al. FASEB JOURNAL
- Neuroprotective Effect of SGLT2 Inhibitors
- (2021) Agnieszka Pawlos et al. MOLECULES
- The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
- (2021) Michael E. Nassif et al. NATURE MEDICINE
- Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
- (2021) Ray Meng See et al. PHARMACOLOGY
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
- (2021) Jonathan V. Mui et al. Frontiers in Cardiovascular Medicine
- Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance
- (2020) Milton Packer CIRCULATION
- The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
- (2020) Hung-Yi Chen et al. Cardiovascular Diabetology
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autophagy in Human Diseases
- (2020) Noboru Mizushima et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of rapamycin on aging and age-related diseases—past and future
- (2020) Ramasamy Selvarani et al. GeroScience
- Sodium‐glucose co‐transporter‐2 inhibitors and all‐cause mortality: A meta‐analysis of randomized controlled trials
- (2020) Giovanni Antonio Silverii et al. DIABETES OBESITY & METABOLISM
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
- (2020) Javed Butler et al. ESC Heart Failure
- Biological Functions of Autophagy Genes: A Disease Perspective
- (2019) Beth Levine et al. CELL
- Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality
- (2019) Gianluigi Savarese et al. CIRCULATION
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- The cardiomyocyte “redox rheostat”: Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death
- (2019) Daniel N. Meijles et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death
- (2019) Ryo Shibusawa et al. Scientific Reports
- 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
- (2019) William E Kraus et al. Lancet Diabetes & Endocrinology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case–control study
- (2019) Ida Kim Wium-Andersen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats
- (2019) Myat Theingi Swe et al. CLINICAL SCIENCE
- Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
- (2018) Adam R. Konopka et al. AGING CELL
- Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and anti-oxidants in diabetic rats.
- (2018) Hiroto Oshima et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Autophagy-Dependent Beneficial Effects of Exercise
- (2017) Jens Frey Halling et al. Cold Spring Harbor Perspectives in Medicine
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- (2017) Jiali Liu et al. Scientific Reports
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
- (2015) Ian J Neeland et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started